Eisai, Biogen Clinch FDA Advisers’ Support for Alzheimer’s Drug

Eisai Co.’s Alzheimer’s disease drug developed with Biogen Inc. gained support from advisers to US regulators, paving the way for a likely full regulatory approval that could lead to broader insurance coverage.

disease fda insurance regulators support